A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity

Detalles Bibliográficos
Autores principales: Garrett, Tracy E, Chekmasova, Alena A, Evans, John W, Seidel, Stacie L, Horton, Holly M, Latimer, Howard J, Griecci, Johanna A, Horvath, Christopher J, Ryu, Byoung Y, Friedman, Kevin M, Morgan, Richard A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645500/
http://dx.doi.org/10.1186/2051-1426-3-S2-P124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645500/
http://dx.doi.org/10.1186/2051-1426-3-S2-P124

Ejemplares similares